157 related articles for article (PubMed ID: 10842191)
1. Disrupted transforming growth factor-beta signaling and deregulated growth in human biliary tract cancer cells.
Yazumi S; Ko K; Watanabe N; Shinohara H; Yoshikawa K; Chiba T; Takahashi R
Int J Cancer; 2000 Jun; 86(6):782-9. PubMed ID: 10842191
[TBL] [Abstract][Full Text] [Related]
2. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
3. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer.
Wagner M; Kleeff J; Lopez ME; Bockman I; Massaqué J; Korc M
Int J Cancer; 1998 Oct; 78(2):255-60. PubMed ID: 9754660
[TBL] [Abstract][Full Text] [Related]
4. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling.
Fanayan S; Firth SM; Baxter RC
J Biol Chem; 2002 Mar; 277(9):7255-61. PubMed ID: 11751851
[TBL] [Abstract][Full Text] [Related]
5. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells.
Chen WB; Lenschow W; Tiede K; Fischer JW; Kalthoff H; Ungefroren H
J Biol Chem; 2002 Sep; 277(39):36118-28. PubMed ID: 12140283
[TBL] [Abstract][Full Text] [Related]
6. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Horie K; Yamashita H; Mogi A; Takenoshita S; Miyazono K
J Cell Physiol; 1998 Jun; 175(3):305-13. PubMed ID: 9572475
[TBL] [Abstract][Full Text] [Related]
7. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
8. Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Hasegawa K; Yazumi S; Wada M; Sakurai T; Kida M; Yamauchi J; Hisatsune H; Tada S; Ida H; Nakase Y; Sakakura C; Hagiwara A; Chiba T
Cancer Sci; 2007 Jun; 98(6):838-43. PubMed ID: 17470130
[TBL] [Abstract][Full Text] [Related]
9. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
[TBL] [Abstract][Full Text] [Related]
10. Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-beta1.
Piek E; Westermark U; Kastemar M; Heldin CH; van Zoelen EJ; Nistér M; Ten Dijke P
Int J Cancer; 1999 Mar; 80(5):756-63. PubMed ID: 10048979
[TBL] [Abstract][Full Text] [Related]
11. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Fanayan S; Firth SM; Butt AJ; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39146-51. PubMed ID: 10993898
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
14. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.
Villanueva A; García C; Paules AB; Vicente M; Megías M; Reyes G; de Villalonga P; Agell N; Lluís F; Bachs O; Capellá G
Oncogene; 1998 Oct; 17(15):1969-78. PubMed ID: 9788440
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
Okamoto M; Oyasu R
Cell Growth Differ; 1997 Aug; 8(8):921-6. PubMed ID: 9269901
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line.
Lee S; Cho YS; Shim C; Kim J; Choi J; Oh S; Kim J; Zhang W; Lee J
Int J Cancer; 2001 Nov; 94(4):500-7. PubMed ID: 11745435
[TBL] [Abstract][Full Text] [Related]
19. Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Montgomery E; Goggins M; Zhou S; Argani P; Wilentz R; Kaushal M; Booker S; Romans K; Bhargava P; Hruban R; Kern S
Am J Pathol; 2001 Feb; 158(2):537-42. PubMed ID: 11159190
[TBL] [Abstract][Full Text] [Related]
20. Anomalies of the TGF-beta postreceptor signaling pathway in ovarian cancer cell lines.
Hu W; Wu W; Nash MA; Freedman RS; Kavanagh JJ; Verschraegen CF
Anticancer Res; 2000; 20(2A):729-33. PubMed ID: 10810347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
